Victory Park Capital announced it has funded newly-launched portfolio company Enteris BioPharma, a developer and manufacturer of proprietary, clinically proven oral dosage formulations and delivery solutions for peptides and small molecule therapeutics.
Enteris said it has named Brian Zietsman, former chief financial officer of Unigene Laboratories, as president and chief financial officer.
“Enteris is a cutting edge biopharmaceutical company,” said Derek Ferguson, investment professional at VPC. “Its official launch marks the first step toward achieving its mission of building long-term strategic relationships with therapeutic partners, while overcoming their challenges in developing oral formulations for both peptides and poorly soluble and permeable small molecules. Enteris’ world-class proprietary technologies are ready to meet these challenges and will provide compelling solutions to industry partners.”